Sign in Subscribe
COVID-19

Researchers Develop Broadly Protective COVID-19 Vaccine Against Sars-cov-2 and Related Coronaviruses

Strategic Insights

— 1 min read

Research conducted at the University of Cambridge has led to the development of a vaccine that elicits broad humoral responses against SARS-CoV-1, SARS-CoV-2, WIV16, and RaTG13 in mice, rabbits, and guinea pigs. The vaccine, designed using a viral-genome-informed computational method, offers protection from the Delta variant of SARS-CoV-2 in mice genetically engineered to express angiotensin-converting enzyme 2 and primed by a viral-vector vaccine. The study's findings suggest that vaccines eliciting broad immune responses across subgroups of coronaviruses may counteract the threat of zoonotic spillovers of betacoronaviruses.

Key Takeaways:

  • The researchers developed a vaccine using a viral-genome-informed computational method that selects immune-optimized and structurally engineered antigens.
  • The vaccine elicits broad humoral responses against SARS-CoV-1, SARS-CoV-2, WIV16, and RaTG13 in mice, rabbits, and guinea pigs.
  • The vaccine offers protection from the Delta variant of SARS-CoV-2 in mice genetically engineered to express angiotensin-converting enzyme 2 and primed by a viral-vector vaccine.
  • The study's findings suggest that vaccines eliciting broad immune responses across subgroups of coronaviruses may counteract the threat of zoonotic spillovers of betacoronaviruses.
  • The vaccine was designed and tested through a collaboration between researchers at the University of Cambridge and other institutions.
  • The study was funded by Innovate UK, COVID (Bavarian Ministry of Science and Arts), and the European Union (EU).
  • The researchers believe that this vaccine approach could be applied to other coronaviruses and may be useful against future pandemics.

Statistics:

  • 4 coronaviruses (SARS-CoV-1, SARS-CoV-2, WIV16, and RaTG13) were targeted by the vaccine.
  • 3 animal species (mice, rabbits, and guinea pigs) were used to test the vaccine.
  • 1 variant (Delta) of SARS-CoV-2 was shown to be protected against by the vaccine.
  • The study was funded by 3 organizations (Innovate UK, COVID, and EU).

Sources:

  • A Computationally Designed Antigen Eliciting Broad Humoral Responses Against Sars-cov-2 and Related Sarbecoviruses. Nature Biomedical Engineering, 2025;9(2).
  • Medical Letter on the CDC & FDA. August 10, 2025; p 162.

Read more